A comparison of fluoride bioavailability from a sustained-release NaF preparation (Neosten) and other fluoride preparations

W. L. Gitomer, K. Sakhaee, C. Y C Pak

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Twelve normal subjects completed a crossover study with sustained-release sodium fluoride (Neosten, 11.3 mg F), monofluorophosphate (MFP, 10 mg F), and plain sodium fluoride (P-NaF, 11.3 mg F). After each preparation was given with 400 mg calcium, serum fluoride (F(ser)) was measured for 24 hours, and pharmacokinetic data were calculated. Fluoride absorption in the Neosten group, as measured by change in the area under the curve (ΔAUC) of F(ser), was less than 33% of that in the MFP and P-NaF treated groups. Both peak F(ser) (C(max)) and peak-basal variation in the Neosten group were 25% that found in the other groups, t( 1/2 ) was nearly twofold greater after Neosten. MFP and P-NaF showed greater bioavailability than Neosten and much higher C(max) that exceeded the toxic threshold of F(ser) (190 ng/ml). These findings could explain the ineffectiveness of MFP and P-NaF observed in recent clinical trials. (C) 2000 the American College of Clinical Pharmacology.

Original languageEnglish (US)
Pages (from-to)138-141
Number of pages4
JournalJournal of Clinical Pharmacology
Volume40
Issue number2
StatePublished - 2000

Fingerprint

Delayed-Action Preparations
Sodium Fluoride
fluorophosphate
Fluorides
Biological Availability
Calcium Fluoride
Poisons
Cross-Over Studies
Area Under Curve
Pharmacokinetics
Clinical Trials
Serum

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{6950972ace554b1eaeff48b4f6e3a2c8,
title = "A comparison of fluoride bioavailability from a sustained-release NaF preparation (Neosten) and other fluoride preparations",
abstract = "Twelve normal subjects completed a crossover study with sustained-release sodium fluoride (Neosten, 11.3 mg F), monofluorophosphate (MFP, 10 mg F), and plain sodium fluoride (P-NaF, 11.3 mg F). After each preparation was given with 400 mg calcium, serum fluoride (F(ser)) was measured for 24 hours, and pharmacokinetic data were calculated. Fluoride absorption in the Neosten group, as measured by change in the area under the curve (ΔAUC) of F(ser), was less than 33{\%} of that in the MFP and P-NaF treated groups. Both peak F(ser) (C(max)) and peak-basal variation in the Neosten group were 25{\%} that found in the other groups, t( 1/2 ) was nearly twofold greater after Neosten. MFP and P-NaF showed greater bioavailability than Neosten and much higher C(max) that exceeded the toxic threshold of F(ser) (190 ng/ml). These findings could explain the ineffectiveness of MFP and P-NaF observed in recent clinical trials. (C) 2000 the American College of Clinical Pharmacology.",
author = "Gitomer, {W. L.} and K. Sakhaee and Pak, {C. Y C}",
year = "2000",
language = "English (US)",
volume = "40",
pages = "138--141",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - A comparison of fluoride bioavailability from a sustained-release NaF preparation (Neosten) and other fluoride preparations

AU - Gitomer, W. L.

AU - Sakhaee, K.

AU - Pak, C. Y C

PY - 2000

Y1 - 2000

N2 - Twelve normal subjects completed a crossover study with sustained-release sodium fluoride (Neosten, 11.3 mg F), monofluorophosphate (MFP, 10 mg F), and plain sodium fluoride (P-NaF, 11.3 mg F). After each preparation was given with 400 mg calcium, serum fluoride (F(ser)) was measured for 24 hours, and pharmacokinetic data were calculated. Fluoride absorption in the Neosten group, as measured by change in the area under the curve (ΔAUC) of F(ser), was less than 33% of that in the MFP and P-NaF treated groups. Both peak F(ser) (C(max)) and peak-basal variation in the Neosten group were 25% that found in the other groups, t( 1/2 ) was nearly twofold greater after Neosten. MFP and P-NaF showed greater bioavailability than Neosten and much higher C(max) that exceeded the toxic threshold of F(ser) (190 ng/ml). These findings could explain the ineffectiveness of MFP and P-NaF observed in recent clinical trials. (C) 2000 the American College of Clinical Pharmacology.

AB - Twelve normal subjects completed a crossover study with sustained-release sodium fluoride (Neosten, 11.3 mg F), monofluorophosphate (MFP, 10 mg F), and plain sodium fluoride (P-NaF, 11.3 mg F). After each preparation was given with 400 mg calcium, serum fluoride (F(ser)) was measured for 24 hours, and pharmacokinetic data were calculated. Fluoride absorption in the Neosten group, as measured by change in the area under the curve (ΔAUC) of F(ser), was less than 33% of that in the MFP and P-NaF treated groups. Both peak F(ser) (C(max)) and peak-basal variation in the Neosten group were 25% that found in the other groups, t( 1/2 ) was nearly twofold greater after Neosten. MFP and P-NaF showed greater bioavailability than Neosten and much higher C(max) that exceeded the toxic threshold of F(ser) (190 ng/ml). These findings could explain the ineffectiveness of MFP and P-NaF observed in recent clinical trials. (C) 2000 the American College of Clinical Pharmacology.

UR - http://www.scopus.com/inward/record.url?scp=0033674518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033674518&partnerID=8YFLogxK

M3 - Article

VL - 40

SP - 138

EP - 141

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 2

ER -